When it comes to treating diabetes, there is definitely more than one way to skin a cat. Multiple drug therapies can be used to keep blood sugars under control because medications work in so many different ways.
The newest addition to oral medications for the treatment of type 2 diabetes, canagliflozin, works by targeting the kidneys and their relationship to blood glucose metabolism and absorption. The drug has undergone intense scrutiny by the FDA and will continue to be mandated to participate in more involved studies, even though it has been released for distribution already.
This new category of drugs are know and SGLT2 inhibitors, and they lower blood sugar by blocking glucose's reabsorption by the kidneys, as well as increasing glucose excretion by the kidneys. Because the mechanism of action is dependent on the kidneys, people on dialysis or with impaired renal function would not be candidates for this new drug. This drug does, however, offer new hope for those type 2 patients who have not achieve blood glucose control on their current medications.